Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesUCB"s Cimzia Approved in the U.S. for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
-- Enzon to receive royalties for PEGylation technology--
Enzon Pharmaceuticals, 05/15/09
Enzon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia, for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia, is a PEGylated anti-TNFa. The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon's PEGylation technology, including PEG-INTRON, Macugen, and Pegasys.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Sponsor
Article Search
Sponsor
Sponsor